Celltrion Begins Global Phase 3 Clinical Trial for Its Bevacizumab Biosimilar 'CT-P16'

World News: . []

Celltrion Inc KRX068270 is set to launch global Phase 3 clinical trial for its bevacizumab biosimilar ‘CT-P16’ for the treatment of cancer Celltrion successfully completed Phase 1 clinical study on the sa fety ...

More news and information about Celltrion, Inc.

Published By:

Business Wire: 06:06 GMT Friday 10th August 2018

Published: .

Search for other references to "celltrion" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us